Vaccines & therapeutic clinical trials to boost COVID-19 prevention and treatment
The 'Vaccines & therapeutic clinical trials to boost COVID-19 prevention and treatment' program, under Horizon Europe, aimed to advance promising COVID-19 vaccine and therapeutic candidates. This initiative supported clinical evaluations, particularly Phase I or II studies, to enrich the portfolio of SARS-CoV-2 prophylactics and therapies and inform public health policy.
Who is Funded: Eligibility and Objectives
This section outlines the eligibility criteria for applicants, the geographical scope of the program, and its primary objectives in combating COVID-19. It details who can apply, where projects should be located, and the strategic goals this funding aims to achieve.
What is Funded: Project Scope and Focus
This section details the types of projects, thematic areas, and activities eligible for funding, alongside information on covered costs and the typical development stage of supported innovations.
Type and Scope of Funding
This section provides essential details about the financial support, including the type of instrument, funding amounts, and expected project durations, helping applicants understand the financial scope.
Conditions and Requirements for Applicants
This section outlines the essential rules and conditions that applicants and beneficiaries must adhere to, covering everything from application terms and collaboration requirements to specific regulatory and budget stipulations.
Application Procedure
This section provides an overview of the application and selection processes, from submission guidelines to how funding decisions are made.
Legal Basis of the Program
This section highlights the foundational legal and official documents that underpin the funding program, ensuring transparency and adherence to established European Union frameworks.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
3,000,000 € to 10,000,000 €
Allocated Budget:
60,000,000 €
Deadline:
20.05.2021
Award Channel:
Framework Programme Call
Region:
EU Member States and associated countries (Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Kosovo, Moldova, Montenegro, Morocco, North Macedonia, Norway, Serbia, Switzerland, Tunisia, Turkey, Ukraine, United Kingdom). Third countries can participate but are generally not eligible for funding.
Sectors:
Healthcare, Medical Technology, Pharmaceutical Industry, Research and Development
Beneficiaries:
Public Health, Medical Research, Pharmaceutical Industry
Application Type:
Consortium Required
Funding Stages:
Applied Research, Experimental Development, Prototyping, Pilot Testing
Funding Provider
Program Level:
European Union
Funding Body:
European Commission
Additional Partners:
European Medicines Agency (EMA), VACCELERATE, RECOVER, EU-RESPONSE projects, COVID-19 data portal
Website: